Sonoma Pharmaceuticals, Inc. (SNOA) is an innovative and leading global brand engaged in the development of stabilized hypochlorous acid products for different applications including wound care, eye care, oral care, nasal care, animal health, disinfectant purposes, and dermatological uses. The wide range of the company’s health care products decreases infections, itching, scars, and severe inflammation effectively.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The price of SNOA stock during the regular trading on January 20, 2022, with a 2.30% decline was $4.25. At last check in the aftermarket, the stock was significantly up by 8.00%.
SNOA: Events and Happenings
On January 20, 2022, SNOA reported about the addition of Salus Medical as an extra distribution partner for oral care and expansion of its dental care product line via a collaboration with Anlicare International. The company along with Salus Medical will dispenseEndocyn root canal irrigant. Additionally, the company’s Microcyn RX and Regenacyn Plus product lines will be used by Salus Medical to expand its novel dermatological offerings.
On January 5, 2022, SNOA reported that the company’s Executives presented at the Virtual H.C. Wainwright BioConnect Conference held on January 10-13, 2022.
SNOA: Key Financials
On November 5, 2021, SNOA reported its financial results for the second fiscal quarter ended September 30, 2021. Some of the key updates are as follows.
Revenue in Q2 2021 was $3.74 million compared to $5.76 million for the same period of 2020. Revenue decreased by $2.02 million or 35% over the year.
Net Income/Loss per Share
Basic and diluted net loss for Q2 2021 was $0.1 million or $0.04 per share compared to net income for the same period of 2020 was $0.12 million or $0.06 per share.
On November 9, 2021, SNOA reported about renewing and expanding its collaboration for multiple indications using the company’sproprietaryMicrocyn Technology for Malaysia, Singapore, Thailand, and Indonesia. On October 15, 2021, SNOA along with its collaborator MicroSafe Group, reported about the approval of extended claims for Nanocyn Disinfectant and Sanitizer developed by the company by the Australian Therapeutic Goods Administration (TGA).
On September 28, 2021, SNOA reported over-the-counter customer unveiling of Regenacyn Advanced Scar Gel, Ocucyn Eye Cleanser andMucoClynson Amazon.com.
SNOA stock is 32% down the past six months due to the recessive economic environment as a result of the spread of pandemics. The current aftermarket surge in the stock is because of the company statement of the expansion of its partnership of dental products in the US. The analysts believe with this momentum to move forward, the company will achieve new heights in the market in the coming days.